Novel antimalarial drugs are urgently needed to treat severe malaria caused by Plasmodium
falciparum. Isoprenoid biosynthesis is a promising target pathway, since the biosynthetic …

Isoprenoid biosynthesis through the methylerythritol phosphate (MEP) pathway generates
commercially important products and is a target for antimicrobial drug development. MEP …

The methylerythritol phosphate (MEP) pathway of Plasmodium falciparum (P. falciparum)
has become an attractive target for anti-malarial drug discovery. This study describes a …

In Plasmodium falciparum the biosynthesis of isoprenoids is achieved by the mevalonate-
independent 1-deoxy-D-xylulose 5-phosphate (DOXP) pathway. The enzymes of the DOXP …

1-Deoxy-d-xylulose 5-phosphate reductoisomerase of Plasmodium falciparum (Pf IspC, Pf
Dxr), believed to be the rate-limiting enzyme of the nonmevalonate pathway of isoprenoid …

1-Deoxy-d-xylulose-5-phosphate reductoisomerase (DXR) in the nonmevalonate isoprene
biosynthesis pathway is a target for developing antimalarial drugs. Fosmidomycin, a potent …

Fosmidomycin inhibits IspC (Dxr, 1-deoxy-d-xylulose 5-phosphate reductoisomerase), a key
enzyme in nonmevalonate isoprenoid biosynthesis that is essential in Plasmodium …

In Plasmodium falciparum, the formation of isopentenyl diphosphate and dimethylallyl
diphosphate, central intermediates in the biosynthesis of isoprenoids, occurs via the …

The emergence of Plasmodium falciparum resistant to frontline therapeutics has prompted
efforts to identify and validate agents with novel mechanisms of action. MEPicides represent …

Abstract Blocking the 2‐C‐methyl‐d‐erythrithol‐4‐phosphate pathway for isoprenoid
biosynthesis offers new ways to inhibit the growth of Plasmodium spp. Fosmidomycin [(3‐(N …